📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Zota Health Care to Seek Shareholder Approval for Increased Investment and Loan Limits
Zota Health Care's Board has approved a proposal to seek shareholder consent via postal ballot to increase limits for loans, guarantees, and investments under Section 186 of the Companies Act, 2013. This move indicates the company is preparing for potential strategic investments or providing financial support to other entities beyond current statutory limits. The cut-off date for voting eligibility was set for March 13, 2026, with the e-voting period concluding on April 16, 2026. Investors should monitor the specific limit amounts and the intended purpose once the detailed postal ballot notice is released.
Key Highlights
Board approved seeking shareholder approval to exceed Section 186 limits for loans, guarantees, and securities.
Cut-off date for determining voting rights for the Postal Ballot is March 13, 2026.
E-voting period is scheduled to run from March 18, 2026, to April 16, 2026.
Mr. Ranjit B. Kejriwal has been appointed as the Scrutinizer for the voting process.
Final results of the postal ballot are expected to be declared by April 17, 2026.
💼 Action for Investors
Investors should review the upcoming Postal Ballot notice to understand the specific financial limits being requested and the company's rationale for potential future investments or loans.
Zota Health Care Launches "All Day Stores" Retail Chain; Plans 50 Outlets in First Phase
Zota Health Care, through its subsidiary Everyday Herbal Beauty Care Limited, is launching a new national retail chain called "All Day Stores" (ADS). The expansion begins with 50 outlets in the first phase, with 15 stores scheduled to open on March 07, 2026, across five Indian states including Gujarat and Maharashtra. Each store will feature over 430 SKUs of private-label products, including personal care and household essentials, in formats ranging from 500 to 1000 square feet. This move represents a strategic forward-integration effort to diversify revenue beyond its existing generic medicine chain, Davaindia.
Key Highlights
Launch of 'All Day Stores' (ADS) retail chain via subsidiary Everyday Herbal Beauty Care Limited
Phase 1 expansion includes 50 outlets, with the first 15 stores opening on March 07, 2026
Stores will offer over 430 SKUs of private-label products across personal care, OTC, and essentials
Initial rollout covers key markets in Gujarat, West Bengal, Maharashtra, Karnataka, and Delhi
Store sizes optimized between 500 to 1000 square feet to ensure a comfortable shopping experience
💼 Action for Investors
Investors should monitor the execution of the store rollout and its impact on consolidated margins, as private-label retail typically offers higher profitability than third-party brands. The success of this diversification beyond generic medicines could be a significant long-term value driver for the company.
Zota Health Care Increases Stake in Subsidiary EHBCL to 87.78% for Rs 19.47 Crore
Zota Health Care has significantly increased its ownership in its subsidiary, Everyday Herbal Beauty Care Limited (EHBCL), by acquiring an additional 21.80% stake. The acquisition was executed via a rights issue subscription for a total consideration of Rs 19.47 crore at Rs 16.50 per share. This transaction raises Zota's total shareholding in EHBCL to 87.78%, up from approximately 66%. EHBCL, which manufactures products under the 'Khadi India' brand, showed robust growth with turnover jumping from Rs 73.39 lakhs in FY24 to Rs 1,144.22 lakhs in FY25.
Key Highlights
Acquired 1,18,00,000 equity shares representing a 21.80% stake in subsidiary EHBCL.
Total investment of Rs 19.47 crore at an acquisition price of Rs 16.50 per share.
Post-acquisition shareholding in EHBCL has increased to 87.78%.
EHBCL reported a significant turnover growth to Rs 1,144.22 lakhs in FY 2024-25.
The move is intended to strengthen backward integration in the cosmetic, ayurvedic, and OTC segments.
💼 Action for Investors
Investors should look favorably on this consolidation of control in a high-growth subsidiary that provides backward integration. Monitor the subsidiary's ability to scale the 'Khadi India' brand and its impact on Zota's consolidated margins.
Zota Health Care Expands Davaindia Network to 2,502 Operational Stores
Zota Health Care has reached a significant milestone with its Davaindia network growing to 2,502 operational stores as of February 11, 2026. This represents a rapid addition of 171 stores since December 31, 2025, when the count stood at 2,331. The current network is comprised of 1,607 Company Owned Company Operated (COCO) stores and 895 Franchisee Owned Franchisee Operated (FOFO) stores. For the current fiscal year, the company has added a total of 920 stores, with a strategic focus on the COCO model which accounted for 755 of those additions.
Key Highlights
Total operational stores reached 2,502 as of February 11, 2026, up from 2,331 in December 2025
Added 920 stores in the current fiscal year, including 755 COCO and 165 FOFO units
COCO stores now make up the majority of the network with 1,607 operational units
The network expansion demonstrates a high execution rate with 171 stores added in approximately 40 days
Strategic focus remains on providing affordable generic medicines through a mix of owned and franchised outlets
💼 Action for Investors
Investors should view this rapid footprint expansion as a positive indicator of scale; however, they should monitor upcoming earnings to see how the increased COCO store count impacts operating margins and capital expenditure.
Zota Health Care Allots 5.71 Lakh Shares; Completes Warrant Conversion Cycle
Zota Health Care has allotted 5,71,961 equity shares to 11 non-promoter investors upon the conversion of the final batch of warrants. The company received Rs. 21.83 Crores as exercise money, representing 75% of the total issue price of Rs. 509 per share. This allotment increases the total paid-up equity capital to Rs. 34.63 Crores. With this conversion, the company has successfully closed the warrant issue initiated in August 2024, with no outstanding warrants remaining.
Key Highlights
Allotment of 5,71,961 equity shares at Rs. 509 per share (including Rs. 499 premium).
Infusion of Rs. 21.83 Crores in capital from 11 non-promoter group investors.
Total paid-up capital increased from 3.40 Crore to 3.46 Crore equity shares.
Zero outstanding warrants remain from the original 26.44 lakh warrant issue.
💼 Action for Investors
The completion of the warrant conversion removes the overhang of future dilution from this specific issue. Investors should monitor how the company utilizes the newly raised capital for growth or debt reduction.
Zota Health Care Q3FY26 Revenue Jumps 98% YoY to ₹143 Cr; Plans 5,000 Stores by 2029
Zota Health Care reported a robust 98.2% YoY revenue growth in Q3FY26, reaching INR 142.95 crore, driven by the aggressive expansion of its Davaindia network. The company added 276 stores during the quarter, bringing the total count to 2,331, while successfully raising INR 350 crore via QIP to fund future growth. Although EBITDA was impacted by pre-operative expenses for approximately 400 stores in the pipeline, management remains confident in reaching 5,000 stores by March 2029. Strategic moves include the acquisition of Curexis and the formation of a new marketing subsidiary to optimize margins.
Key Highlights
Consolidated revenue surged 98.2% YoY to INR 142.95 crore, with Davaindia contributing 80% of total sales.
Added 276 new stores in Q3, taking the total Davaindia footprint to 2,331 stores across 23 states and 5 UTs.
Successfully completed a INR 350 crore QIP to accelerate the rollout of Company-Owned Company-Operated (COCO) stores.
Quarterly customer footfall nearly doubled to 49 lakhs compared to 27 lakhs in the previous year.
Acquired 100% stake in Curexis (SKIA brand) and incorporated KMHP Ventures for better sourcing and distribution.
💼 Action for Investors
Investors should monitor the margin recovery as the 400+ stores currently under development become operational and start contributing to the bottom line. The successful QIP provides a strong capital cushion for the company's ambitious 5,000-store target by 2029.
Zota Health Care Q3FY26: Davaindia Network Expands to 2,331 Stores; 9M Revenue at ₹375.48 Cr
Zota Health Care reported a consolidated revenue of ₹37,548 lakhs for 9MFY26, with its Davaindia retail chain contributing 73% of the total. The company has aggressively expanded its retail footprint to 2,331 stores, focusing on the more profitable COCO (Company-Owned Company-Operated) model which now stands at 1,438 units. Strategic integration through a 65.98% stake in Everyday Herbal Group and a growing export portfolio of 325 approved products highlight diversified growth. The business model focuses on providing generic medicines at 30-90% lower costs than branded competitors.
Key Highlights
9MFY26 Consolidated Revenue stood at ₹37,548 lakhs with a Gross Profit of ₹22,113 lakhs.
Davaindia retail network reached 2,331 active stores, including 1,438 COCO and 893 FOFO outlets.
Davaindia segment dominates the revenue mix at 73%, followed by Domestic Marketing at 15%.
Export operations have 325 product approvals across 30+ countries, with 586 total dossier applications.
Strategic backward integration completed with a 65.98% stake in Everyday Herbal Group for OTC expansion.
💼 Action for Investors
Investors should track the margin improvement as the company shifts towards the COCO model and scales its OTC portfolio. The aggressive retail expansion positions Zota as a key player in the affordable healthcare segment.
Zota Health Care Q3FY26 Revenue Surges 98.2% YoY to ₹142.95 Cr; Store Count Hits 2,331
Zota Health Care reported a massive 98.2% YoY revenue growth in Q3FY26, reaching ₹14,295.14 lakhs, primarily driven by the rapid expansion of its Davaindia generic pharmacy network. While the company turned EBITDA positive on a YoY basis, margins were significantly squeezed sequentially to 0.89% due to high pre-opening costs for over 400 stores currently under development. The company added 276 stores during the quarter, bringing the total to 2,331, and successfully raised ₹350 crore via QIP to fund further expansion. Management maintains a long-term target of reaching 5,000 stores by March 2029.
Key Highlights
Consolidated Revenue grew 98.2% YoY to ₹14,295.14 lakhs, with Davaindia sales jumping 150% YoY to ₹11,479.27 lakhs.
Gross margins improved to 60.28% from 55.86% YoY, reflecting better scale and product mix.
EBITDA turned positive at ₹127.58 lakhs compared to a loss of ₹556.47 lakhs in Q3FY25, though it fell sharply from Q2FY26 levels.
Davaindia network expanded to 2,331 stores nationwide, with 276 new stores added in Q3FY26 alone.
Successfully completed a ₹350 crore QIP to support the rollout of Company-Owned Company-Operated (COCO) stores.
💼 Action for Investors
Investors should monitor the unit economics of the Davaindia stores as the company prioritizes rapid scale over immediate profitability. While the top-line growth is exceptional, the impact of pre-opening expenses on margins warrants a cautious approach until operating leverage kicks in.
Zota Health Care Q3 Revenue Surges 60% YoY; Approves 100% Acquisition of Curexis Ventures
Zota Health Care reported a strong standalone performance for Q3 FY26, with revenue growing 60% YoY to ₹108.88 crore and net profit rising to ₹6.01 crore. The Board has approved the 100% acquisition of Curexis Ventures Private Limited and a further investment in its subsidiary, Davaindia Health Mart Limited, via a rights issue. While standalone growth is robust, the consolidated financials are weighed down by significant losses from subsidiaries, which reported a net loss of ₹34.51 crore for the quarter. Investors should focus on the integration of the new acquisition and the path to profitability for the retail pharmacy segment.
Key Highlights
Standalone revenue for Q3 FY26 grew 59.8% YoY to ₹108.88 crore from ₹68.13 crore.
Standalone net profit for the quarter increased nearly 3x to ₹6.01 crore compared to ₹2.08 crore in the previous year.
Board approved the 100% acquisition of Curexis Ventures Private Limited to expand its healthcare portfolio.
Subsidiaries reported a combined net loss of ₹34.51 crore for the quarter, impacting overall consolidated performance.
Company to subscribe to 58,827 equity shares of Davaindia Health Mart Limited via a rights issue to support its subsidiary.
💼 Action for Investors
Investors should monitor the turnaround progress of the Davaindia subsidiary as its losses are currently offsetting the strong standalone growth. The acquisition of Curexis Ventures is a key expansion move that warrants a watch on integration and synergy benefits.
Zota Health Care Q3 Standalone PAT Triples to ₹6.01 Cr; Approves 100% Curexis Ventures Acquisition
Zota Health Care reported a robust standalone performance for Q3 FY26, with revenue from operations surging 60% YoY to ₹108.88 crore. Standalone Net Profit grew significantly to ₹6.01 crore from ₹2.08 crore in the same period last year. The company also announced strategic moves including the 100% acquisition of Curexis Ventures Private Limited and further investment in its subsidiary, Davaindia Health Mart. However, consolidated results highlight significant losses in subsidiaries, with a quarterly net loss of ₹34.51 crore from those units.
Key Highlights
Standalone revenue from operations increased 60% YoY to ₹108.88 crore in Q3 FY26.
Standalone Net Profit rose to ₹6.01 crore for the quarter, up from ₹2.08 crore in Q3 FY25.
Board approved the 100% acquisition of Curexis Ventures Private Limited.
Subscribed to 58,827 equity shares of wholly-owned subsidiary Davaindia Health Mart via rights issue.
Consolidated subsidiaries reported a combined net loss of ₹34.51 crore for the quarter ended December 31, 2025.
💼 Action for Investors
While standalone growth is impressive, investors should closely monitor the high losses in subsidiaries which are impacting consolidated profitability. The integration of Curexis Ventures and the performance of the Davaindia retail chain remain key variables for future valuation.
Zota Health Care Q3 Standalone PAT Jumps 189% YoY; Board Approves Curexis Ventures Acquisition
Zota Health Care reported a strong standalone performance for Q3 FY26, with revenue rising 60% YoY to ₹108.88 crore and PAT surging to ₹6.01 crore. However, the consolidated outlook remains pressured as subsidiaries reported a combined net loss of ₹34.51 crore for the quarter. The company is actively expanding, approving the 100% acquisition of Curexis Ventures Private Limited and further capital infusion into its subsidiary, Davaindia Health Mart. A new Risk Management Committee has also been established to oversee the company's growing operational complexity.
Key Highlights
Standalone Revenue from Operations grew 59.8% YoY to ₹108.88 crore in Q3 FY26.
Standalone Net Profit increased by 189% YoY, reaching ₹6.01 crore compared to ₹2.08 crore in the previous year.
Board approved the 100% acquisition of Curexis Ventures Private Limited to strengthen market position.
Subsidiaries contributed ₹77.44 crore to revenue but incurred a significant net loss of ₹34.51 crore during the quarter.
Approved subscription to a rights issue for 58,827 equity shares of wholly-owned subsidiary Davaindia Health Mart Limited.
💼 Action for Investors
Investors should weigh the impressive standalone growth against the heavy losses in the Davaindia subsidiary, which continue to drag down consolidated performance. Monitor the integration of Curexis Ventures and the timeline for subsidiary break-even before increasing exposure.
Zota's Davaindia Hits 2,331 Stores; Independent Study Validates 100% Generic Drug Quality
Zota Health Care's Davaindia chain has been validated by an independent MESH study, confirming 100% quality compliance across 131 generic medicines compared to branded equivalents. The company reported a total of 2,331 stores as of December 31, 2025, having added 276 stores in Q3 FY26 alone. Davaindia's business model offers 30-90% savings over branded drugs, attracting 16 lakh monthly customers with a high 80% repeat rate. Furthermore, the company has strengthened its capital position by raising ₹350 crore through a QIP.
Key Highlights
Independent MESH study validates 100% quality compliance for Davaindia generics across 22 therapeutic categories.
Total store network reached 2,331 outlets as of Dec 31, 2025, with 276 new stores added in Q3 FY26.
Generic medicines priced 30% to 90% lower than branded equivalents across a portfolio of 2,000+ SKUs.
Strong customer loyalty demonstrated by an 80% repeat purchase rate and 16 lakh monthly customers.
Successfully raised ₹350 crore through a QIP to support nationwide expansion and working capital.
💼 Action for Investors
The independent quality validation is a significant brand-building milestone that should help overcome consumer skepticism regarding generic medicines. Investors should monitor the execution of the new COCO stores and the utilization of QIP funds to drive further market share in the organized pharmacy retail space.
Zota Health Care to Invest Rs 170 Crore in Subsidiary Davaindia for Retail Expansion
Zota Health Care Limited has announced a significant investment of Rs 169.99 crores in its wholly-owned subsidiary, Davaindia Health Mart Limited (DIHML), via a rights issue. The funds are earmarked for the strategic expansion of Company Owned Company Operated (COCO) stores and to support working capital needs. DIHML has demonstrated impressive growth, with its turnover surging from Rs 14.61 crores in FY23 to Rs 109.93 crores in FY25. This move strengthens Zota's footprint in the generic pharmacy retail space, where it currently operates 1,438 stores.
Key Highlights
Investment of Rs 169.99 crores through the acquisition of 3,95,348 shares at Rs 4,300 each.
Davaindia's turnover increased significantly from Rs 14.61 Cr in FY23 to Rs 109.93 Cr in FY25.
The subsidiary manages a network of 1,438 stores across 25 states and 5 Union Territories as of Dec 2025.
Capital will be utilized for expanding the COCO store model and meeting operational requirements.
💼 Action for Investors
This capital infusion highlights Zota's aggressive growth strategy in the high-potential generic medicine retail market. Investors should track the scaling of the COCO model and its contribution to overall consolidated profitability.
Zota Health Care Allots 1.07 Lakh Equity Shares on Warrant Conversion at Rs 509/share
Zota Health Care Limited has allotted 1,07,556 equity shares to three non-promoter investors upon the conversion of warrants. The conversion occurred at an issue price of Rs 509 per share, bringing in approximately Rs 4.11 crore in exercise money. This move has increased the company's total paid-up equity capital to Rs 33.88 crore. Currently, 7,51,130 warrants remain outstanding for future conversion within the 18-month window.
Key Highlights
Allotment of 1,07,556 equity shares at Rs 509 per share including Rs 499 premium
Receipt of Rs 4.11 crore as 75% warrant exercise money from non-promoter group
Total paid-up capital increased to Rs 33.88 crore from Rs 33.77 crore
7,51,130 warrants remain outstanding from the original August 2024 issuance
💼 Action for Investors
The conversion indicates investor confidence at the Rs 509 price point; however, shareholders should be aware of the gradual equity dilution as the remaining warrants are converted.
Zota Health Care Expands Davaindia Network to 2,331 Stores with 276 New Openings in Q3FY26
Zota Health Care has reported a robust expansion of its Davaindia retail chain, adding 276 new stores during Q3FY26. This brings the total store count to 2,331 as of December 31, 2025, up from 2,055 at the end of the previous quarter. The growth was heavily weighted toward Company Owned Company Operated (COCO) stores, which saw 231 new additions. This aggressive scaling strategy indicates the company's commitment to increasing its market share in the generic pharmacy retail segment.
Key Highlights
Total Davaindia store count reached 2,331 as of December 31, 2025
Added 276 new stores during the Q3FY26 period
COCO stores increased by 231 units to a total of 1,438
FOFO stores grew by 45 units to reach a total of 893
Expansion reflects a strong focus on the COCO model managed by its wholly owned subsidiary
💼 Action for Investors
Investors should view this rapid footprint expansion as a positive lead indicator for future revenue growth. Monitor upcoming earnings to see if the increased store count translates into improved operating leverage and profitability.
Zota Health Care Raises Rs 350 Crores via QIP at Rs 1,535 Per Share
Zota Health Care has successfully completed a Rs 350 crore fundraise through a Qualified Institutional Placement (QIP), allotting 22.80 lakh shares at Rs 1,535 each. The issue attracted marquee investors including White Oak Capital, 360 ONE, and Prashant Jain-led 3P Investment Managers. The proceeds are primarily earmarked for the aggressive expansion of the 'Davaindia' generic pharmacy chain, aiming to scale from 2,253 stores to over 5,000 stores by March 2029. This capital infusion significantly strengthens the company's balance sheet for its next phase of growth in the affordable medicine segment.
Key Highlights
Raised Rs 350 crores by issuing 22,80,130 equity shares at a price of Rs 1,535 per share
Participation from marquee investors including Valiant Partners, White Oak Capital, and 3P Investment Managers
Funds to drive expansion of Davaindia stores from current 2,253 to over 5,000 by March 2029
Current store network includes 1,373 Company-Owned (COCO) and 880 Franchisee-Owned (FOFO) outlets
Proceeds also allocated for working capital requirements and general corporate purposes
💼 Action for Investors
The participation of high-profile institutional investors provides a strong valuation benchmark and validation of the Davaindia business model. Investors should monitor the company's ability to maintain per-store profitability while doubling its store count over the next four years.
Zota Health Care Allots 6.02 Lakh Equity Shares on Warrant Conversion at Rs 820/share
Zota Health Care Limited has successfully completed the conversion of its remaining 6,02,500 warrants into equity shares at an issue price of Rs 820 per share. This final tranche of conversion has brought in approximately Rs 37.05 crore in warrant exercise money from non-promoter institutional investors. Following this allotment, the company's paid-up equity capital has increased to Rs 33.77 crore, representing 3,37,73,901 shares. With this action, there are no outstanding warrants left from the original February 2025 preferential issuance.
Key Highlights
Allotment of 6,02,500 equity shares at a premium price of Rs 820 per share
Total capital inflow of Rs 37.05 crore received as 75% warrant exercise money
Key institutional allottees include 3P India Equity Fund and Valiant India Opportunities Ltd
Total paid-up equity shares increased from 3.31 crore to 3.37 crore
Zero outstanding warrants remain from the original 7,52,500 warrants issued in Feb 2025
💼 Action for Investors
The successful conversion of warrants at a significant premium by institutional investors signals strong external confidence in Zota's business model. Investors should monitor the company's upcoming quarterly results to see how this fresh capital is deployed for growth.
Zota Health Care Raises ₹350 Crore via QIP; Allots 22.8 Lakh Shares at ₹1,535 Each
Zota Health Care has successfully completed a Qualified Institutional Placement (QIP), raising approximately ₹350 crore. The company allotted 22.80 lakh equity shares to institutional investors at an issue price of ₹1,535 per share, which included a 4.97% discount to the floor price. This fundraise has increased the company's paid-up equity capital from ₹30.89 crore to ₹33.17 crore. The issue saw strong participation from marquee investors like Valiant Mauritius Partners and Ashoka Whiteoak, signaling high institutional confidence.
Key Highlights
Allotted 22,80,130 equity shares at ₹1,535 per share, aggregating to ₹349.99 crore.
The issue price includes a discount of ₹80.28 (4.97%) on the floor price.
Total paid-up equity share capital increased to 3,31,71,401 shares post-allotment.
Valiant Mauritius Partners (Offshore and Limited) emerged as the largest allottees, taking up over 42% of the issue.
Other major participants include Ashoka Whiteoak India Opportunities Fund (11.65%) and Sanshi Fund-I (7.14%).
💼 Action for Investors
The successful capital raise and entry of high-quality institutional investors are positive indicators for the company's growth trajectory. Investors should monitor the company's upcoming quarterly results to see how this capital is deployed for expansion or debt reduction.
Zota Health Care Closes QIP to Raise ₹350 Crore at ₹1,535 Per Share
Zota Health Care Limited has successfully concluded its Qualified Institutions Placement (QIP) on December 17, 2025. The company approved the allotment of 22,80,130 equity shares to qualified institutional buyers at an issue price of ₹1,535 per share. This issue price includes a discount of 4.97% on the floor price of ₹1,615.28. The total capital raised through this placement is approximately ₹350 crore, which strengthens the company's balance sheet for future growth initiatives.
Key Highlights
Allotment of 22,80,130 equity shares of face value ₹10 each to eligible QIBs.
Issue price fixed at ₹1,535 per share, including a premium of ₹1,525.
Applied a discount of ₹80.28 per share (4.97%) on the floor price of ₹1,615.28.
Total fundraise size is approximately ₹350 crore.
The QIP process was completed within three days, opening on December 15 and closing on December 17, 2025.
💼 Action for Investors
Investors should view the successful institutional fundraise as a sign of confidence in the company's growth prospects. Monitor the company's upcoming quarterly results to see how the fresh capital is deployed for expansion or debt reduction.
Zota Health Care Closes QIP; Allots 22.8 Lakh Shares at ₹1,535 Per Share
Zota Health Care has successfully concluded its Qualified Institutions Placement (QIP) on December 17, 2025. The company approved the allotment of 22,80,130 equity shares to qualified institutional buyers at an issue price of ₹1,535 per share. This price reflects a 4.97% discount to the floor price of ₹1,615.28 per share. The total fundraise amounts to approximately ₹350 crore, which strengthens the company's balance sheet for future growth initiatives.
Key Highlights
Allotment of 22,80,130 equity shares of face value ₹10 each to eligible QIBs
Issue price fixed at ₹1,535 per share, including a premium of ₹1,525
Applied a discount of ₹80.28 per share (4.97%) on the floor price of ₹1,615.28
The QIP issue period was open from December 15 to December 17, 2025
Total capital raised through the placement is approximately ₹350 crore
💼 Action for Investors
The successful QIP at a minimal discount indicates strong institutional demand and provides the company with significant growth capital. Investors should monitor how the management deploys these funds to drive earnings growth.